When was FimmCyte founded?

FimmCyte was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is FimmCyte located?

FimmCyte is headquartered in Basel, Switzerland.

How many employees does FimmCyte have?

As of Sep 30, 2026, the latest employee count at FimmCyte is 7.

Is FimmCyte a funded company?

FimmCyte is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 13, 2022.

When was the latest funding round of FimmCyte?

FimmCyte's latest funding was a $***** Conventional Debt round on Feb 29, 2024, with participation from 1 investor. Its primary sector is Women Health. Globally, the Women Health sector has seen $252M in funding in 2026 to date.

Where does FimmCyte rank among its competitors?

FimmCyte ranks 7th amongst 46 active competitors, of which 12 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Rejoni, which secured $25M in Jun, 2026.

Who are the top competitors of FimmCyte?

FimmCyte's top competitors include Rejoni, Sprout Pharmaceuticals and Gameto. Among them, Rejoni secured the most recent funding round in June, 2026.

FimmCyte - 2026 Company Profile, Team, Funding & Competitors

FimmCyte is a funded company based in Basel (Switzerland), founded in 2022 by Valentina Vongrad. It operates as a Developer of therapeutics to treat endometriosis. FimmCyte has raised an undisclosed amount in funding. The company has 46 active competitors, including 12 funded and 7 that have exited. Its top competitors include companies like Rejoni, Sprout Pharmaceuticals and Gameto.

Company Details

Developer of therapeutics to treat endometriosis. It offers non-hormonal drugs that use the women’s immune system to selectively destroy the diseased endometriotic tissue with precision.

Website: fimmcyte.com
Email ID: *****@fimmcyte.com

Key Metrics

Founded Year

2022

Location

Basel, Switzerland

Stage

Funding Raised

Latest Funding Round

Conventional Debt, Feb 29, 2024, $*****

Investors

BaseLaunch & 3 more

Ranked

7^th among 46 active competitors

Employee Count

7 as on Sep 30, 2026

Similar Companies

Rejoni & 45 more

View FimmCyte's full profile

FimmCyte has raised funding over 2 rounds. Its first funding round was on Jul 13, 2022. Its latest funding round was a Conventional Debt round on Feb 29, 2024 for $*****. 1 investor participated in its latest round. FimmCyte has 4 institutional investors.

Here is the list of recent funding rounds of FimmCyte:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 29, 2024	7956563	Conventional Debt	7710931	9667425	8630262	8602179
Jul 13, 2022	1255896	Grant (prize money)	1897637	9615765	7366761	Venture Kick

Access funding benchmarks and valuations. Sign up today!

View details of FimmCyte's funding rounds and investors

The founders of FimmCyte is Valentina Vongrad.

Here are the details of FimmCyte's key team members:

Valentina Vongrad: Co-Founder of FimmCyte.

View details of FimmCyte's Founder profiles and Board Members

FimmCyte's employee count trend

FimmCyte has 7 employees as of Sep 26. Here is FimmCyte's employee count trend over the years:

Uncover FimmCyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of FimmCyte include Rejoni, Sprout Pharmaceuticals and Gameto. Here is the list of Top 10 competitors of FimmCyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rejoni 2020, Bedford (United States), Series B	Developer of therapeutics to treat women health conditions	$66.3M	Ascension Ventures, CHV & 8 others	61/100
2nd	Sprout Pharmaceuticals 2011, Raleigh (United States), Acquired	Developer of drugs for hypoactive sexual desire disorder in women	$185M	New Ventures Funds, Lunsford Capital & 1 others	57/100
3rd	Gameto 2020, United States, Series C	Developer of therapeutics for the treatment of fertility and menopause	$127M	RA Capital Management, Two Sigma Ventures ... & 30 others	57/100
4th	Hope Medicine 2018, Shanghai (China), Series B	Developer of monoclonal antibodies for the treatment of multiple diseases	$56M	Qiming Venture Partners, Ennovation Ventures ... & 7 others	55/100
5th	Naari 2007, Noida (India), Acquired	Manufacturer of women care medicines	$19M	Ascent Capital, Jagsonpal & 18 others	52/100
6th	Lighthouse Pharma 2019, San Francisco (United States), Series A	Developer of therapeutics for neurology and infectious diseases	$15.2M	Double Point Ventures, HHS	51/100
7th	FimmCyte 2022, Basel (Switzerland), Funding Raised	Developer of therapeutics to treat endometriosis	-	BaseLaunch, Venture Kick & 2 others	45/100
8th	PregLem 2006, Geneva (Switzerland), Acquired	Drugs for women's reproductive medicine	$57.9M	MVM, NeoMed & 2 others	44/100
9th	ObsEva 2012, Geneva (Switzerland), Public	Developer of therapeutics for women's reproductive health and pregnancy	$94.7M	Sofinnova Partners, Rock Springs Capital ... & 17 others	44/100
10th	Forendo Pharma 2013, Turku (Finland), Acquired	Provider of small molecule based therapeutics for reproductive health	$25.6M	Sunstone, Novo Holdings & 8 others	44/100